- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 271/07 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 271/07
Total number of patents in this class: 165
10-year publication summary
13
|
22
|
15
|
10
|
15
|
10
|
6
|
15
|
10
|
2
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Theravance Biopharma R&D IP, LLC | 460 |
6 |
Farmington Pharma Development | 7 |
5 |
Oryzon Genomics S.A. | 106 |
5 |
Novassay S.A. | 10 |
4 |
Romark Laboratories L.C. | 52 |
4 |
Janssen Pharmaceutica N.V. | 3396 |
3 |
Bayer Intellectual Property GmbH | 2509 |
3 |
Bayer Cropscience AG | 2051 |
3 |
Bayer Pharma AG | 1061 |
3 |
King Faisal University | 908 |
3 |
The Board of Regents of the University of Texas System | 2204 |
3 |
Calico Life Sciences LLC | 96 |
3 |
Merck Sharp & Dohme LLC | 3751 |
3 |
Bristol-myers Squibb Company | 4879 |
2 |
BASF SE | 20892 |
2 |
Boehringer Ingelheim International GmbH | 4697 |
2 |
Abbvie Inc. | 1800 |
2 |
Takeda Pharmaceutical Company Limited | 2712 |
2 |
Vertex Pharmaceuticals Incorporated | 1595 |
2 |
Northwestern University | 3374 |
2 |
Other owners | 103 |